SCHEMBL2666636

SCHEMBL2666636

O[C@@H]1CC[C@@H](O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL178572 1.00
SCHEMBL33452 1.00
SCHEMBL3066197 1.00
SCHEMBL16675542 0.95 LMNA (0.47)
SCHEMBL8022298 0.95 TSHR (0.50)
SCHEMBL27274822 0.95
SCHEMBL9066346 0.95 TSHR (0.50)
SCHEMBL15484250 0.95 LMNA (0.47)
SCHEMBL20895863 0.84 TSHR (0.60)
SCHEMBL1492517 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368983-A1 CONTROLLING FOR TAGMENTATION SEQUENCING LIBRARY INSERT SIZE USING ARCHAEAL HISTONE-LIKE PROTEINS KAPA BIOSYSTEMS INC (US) 2025-12-04 US disclosed
EP-4652164-A1 INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2025-11-26 EP disclosed
US-20250213555-A1 SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-07-03 US disclosed
WO-2024233812-A1 INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2024-11-14 WO disclosed
WO-2024046992-A1 IMPROVEMENTS TO NEXT-GENERATION TARGET ENRICHMENT PERFORMANCE F. HOFFMANN-LA ROCHE AG (CH) 2024-03-07 WO disclosed
CN-115184120-A Fixative composition for cell-containing liquid samples 凯杰有限公司 2022-10-14 CN disclosed
US-20220324835-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. 2022-10-13 US disclosed
CN-108473464-B Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity 阿斯泰克斯治疗有限公司 2022-08-23 CN disclosed
EP-3149446-B1 FIXATIVE COMPOSITION FOR CELL-COMPRISING LIQUID SAMPLES QIAGEN GMBH (DE) 2022-07-06 EP disclosed
US-11261171-B1 Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity ASTEX THERAPEUTICS LIMITED (GB) 2022-03-01 US disclosed
EP-2126542-A1 FIXATION OF A BIOLOGICAL MATERIAL Qiagen GmbH (DE) 2009-12-02 EP disclosed
EP-2048170-A2 Second catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer Sumitomo Chemical Company, Limited (JP) 2009-04-15 EP disclosed
EP-2048167-A2 First catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer Sumitomo Chemical Company, Limited (JP) 2009-04-15 EP disclosed
EP-2048168-A2 Process for producing catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer Sumitomo Chemical Company, Limited (JP) 2009-04-15 EP disclosed
WO-2008104564-A1 FIXATION OF A BIOLOGICAL MATERIAL QIAGEN GMBH (DE) 2008-09-04 WO disclosed
WO-2007007886-A1 AN OXIME DERIVATIVE AND PREPARATIONS THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-01-18 WO disclosed
EP-0882714-B1 SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME SS PHARMACEUTICAL CO (JP) 2004-03-03 EP disclosed
US-5935977-A PHOSPHODIESTERASE IV INHIBITORS, TUMOR NECROSIS FACTOR-ALPHA PRODUCTION INHIBITORS; TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES SS PHARMACEUTICAL CO., LTD. (JP) 1999-08-10 US disclosed
EP-0882714-A1 SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME SS Pharmaceutical Co., Ltd. (JP) 1998-12-09 EP disclosed
WO-1996031476-A1 AROMATIC HYDROXYETHERS RHONE-POULENC RORER LIMITED (GB) 1996-10-10 WO disclosed